Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

por Rossignol, Jean-François
Publicado 2016

Nitazoxanide: A first-in-class broad-spectrum antiviral agent

por Rossignol, Jean-François
Publicado 2014

Rethinking methods used to evaluate effectiveness of therapeutics for COVID-19 and other viral respiratory illnesses

por Rossignol, Jean-François
Publicado 2022

A Pilot Clinical Trial of Nitazoxanide in the Treatment of Chronic Hepatitis B

por Rossignol, Jean‐François, Bréchot, Christian
Publicado 2019

A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19

por Rossignol, Jean-François, Bardin, Matthew C., Fulgencio, Jessica, Mogelnicki, Dena, Bréchot, Christian
Publicado 2022

Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence

por Riccio, Anna, Santopolo, Silvia, Rossi, Antonio, Piacentini, Sara, Rossignol, Jean-Francois, Santoro, M. Gabriella
Publicado 2022

Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs

por Stachulski, Andrew V., Swift, Karl, Cooper, Mark, Reynolds, Stephen, Norton, Daniel, Slonecker, Steven D., Rossignol, Jean-François
Publicado 2017

Thiazolides: A New Class of Broad-Spectrum Antiviral Drugs Targeting Virus Maturation

por Santoro, M. Gabriella, Ciucci, Alessandra, Gianferretti, Patrizia, Belardo, Giuseppe, La Frazia, Simone, Carta, Stefania, Rossignol, Jean-Francois
Publicado 2007

Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial

por Haffizulla, Jason, Hartman, Aaron, Hoppers, Melanie, Resnick, Harvey, Samudrala, Steve, Ginocchio, Christine, Bardin, Matthew, Rossignol, Jean-François
Publicado 2014

The Modulation of Cholesterol Metabolism Is Involved in the Antiviral Effect of Nitazoxanide

por Fenizia, Claudio, Ibba, Salomè Valentina, Vanetti, Claudia, Strizzi, Sergio, Rossignol, Jean-François, Biasin, Mara, Trabattoni, Daria, Clerici, Mario
Publicado 2021

The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein

por Piacentini, Sara, Riccio, Anna, Santopolo, Silvia, Pauciullo, Silvia, La Frazia, Simone, Rossi, Antonio, Rossignol, Jean-Francois, Santoro, M. Gabriella
Publicado 2023

Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication

por Trabattoni, Daria, Gnudi, Federica, Ibba, Salomè V., Saulle, Irma, Agostini, Simone, Masetti, Michela, Biasin, Mara, Rossignol, Jean-Francois, Clerici, Mario
Publicado 2016

Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57

por Piacentini, Sara, La Frazia, Simone, Riccio, Anna, Pedersen, Jens Z., Topai, Alessandra, Nicolotti, Orazio, Rossignol, Jean-Francois, Santoro, M. Gabriella
Publicado 2018

Viral burden, inflammatory milieu and CD8(+) T‐cell responses to influenza virus in a second‐generation thiazolide (RM‐5061) and oseltamivir combination therapy study

por Nüssing, Simone, Mifsud, Edin, Hensen, Luca, Koutsakos, Marios, Wang, Zhongfang, Kedzierski, Lukasz, Mercuri, Francesca, Rossignol, Jean‐Francois, Hurt, Aeron C., Kedzierska, Katherine
Publicado 2020

Thiazolide Prodrug Esters and Derived Peptides: Synthesis and Activity

por Stachulski, Andrew V., Rossignol, Jean-Francois, Pate, Sophie, Taujanskas, Joshua, Iggo, Jonathan A., Aerts, Rudi, Pascal, Etienne, Piacentini, Sara, La Frazia, Simone, Santoro, M. Gabriella, van Vooren, Lieven, Sintubin, Liesje, Cooper, Mark, Swift, Karl, O’Neill, Paul M.
Publicado 2023